REUTERS

Johnson & Johnson to Present New Data for Investigational Preventive Vaccine and Single-Tablet Treatment Regimens for HIV-1 at AIDS 2018

Originally Published by Johnson & Johnson.

As part of its commitment to make HIV history, the Janssen Pharmaceutical Companies of Johnson & Johnson announced that over ten company-sponsored and partnered presentations will be presented at the 22nd International AIDS Conference (AIDS 2018) in Amsterdam, The Netherlands (23-27 July). Johnson & Johnson will also be hosting a major satellite symposium, Biomedical Research Innovations in the Prevention, Remission and Cure of HIV/AIDS, which will take place immediately prior to the opening ceremony of the conference on July 23.


Notable Janssen presentations at AIDS 2018 will include the first long-term immunological data for the company’s investigational preventive vaccine regimen against HIV-1. Janssen’s mosaic-based regimen is designed as a “global vaccine” with the goal of preventing HIV infections due to a wide variety of HIV-1 subtypes responsible for the worldwide pandemic. Findings up to one year after last vaccination on safety and immunogenicity (ability to elicit an immune response) will be presented from the Phase 1/2a APPROACH study. Initial data from APPROACH were published in The Lancet on July 6, 2018, and showed a robust HIV immune response among a high percentage of healthy volunteers.

“The progress made in the last thirty years in the fight against HIV is remarkable, yet there is still much more to be done to achieve the UN’s target of ending the epidemic by 2030,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson. “In our quest towards a world without HIV, we are partnering with others to achieve the very best science. From our clinical trials of an investigational vaccine to exploring ways to transform the efficacy and tolerability of therapy, we aim to change the trajectory of health for humanity.”

Janssen will also present new data for SYMTUZATM, the darunavir-based single-tablet regimen for the treatment of HIV-1 infection, for which FDA approval is pending. These data include Week 48 results from the pivotal EMERALD trial, providing evidence on the efficacy and safety of switching from a boosted protease inhibitor-based regimen to a single-tablet regimen of SYMTUZATM in the treatment of HIV-1. Results from subgroups according to baseline regimen will be presented.

Johnson & Johnson is also proud to support its partners at AIDS 2018, harnessing extensive resources, pushing boundaries and exploring solutions to tackle some of the today’s most pressing public health challenges. Johnson & Johnson is committed to reducing the burden of HIV among the world’s most underserved populations through collaborations exploring multiple solutions, from investigating the role of a dapivirine-coated vaginal ring and its potential to reduce HIV transmission, to how cellphones may be used to support adherence to antiretroviral therapy.

A selected list of company and partnered data is listed below:

New data for our investigational vaccine regimen

APPROACH: This Phase 1/2a study will describe long-term safety and immunogenicity data in humans for investigational “mosaic”-based, prime-boost regimens that are designed to elicit an immune response against a variety of HIV subtypes prevalent worldwide.

  • Oral presentation from 11:45 CEST (05:45 EDT) on Tuesday 24 July (Abstract #10764); Venue E105-108

HPX1002/IPCAVD010: This Phase 1 study explores the immunologic responses of shorter mosaic-based vaccine regimens.

  • Oral presentation by Janssen’s partner Beth Israel Deaconess Medical Center (BIDMC) from 12:00 CEST (06:00 EDT) on Tuesday 24 July (Abstract #11441); Venue E105-108

New data for SYMTUZATM, the darunavir-based single-tablet regimen
EMERALD: Week 48 data in the pivotal EMERALD trial of HIV-1, providing evidence on the efficacy and safety of switching from a boosted protease inhibitor-based regimen to a single-tablet regimen of SYMTUZATM. Results from subgroups according to baseline regimen with be presented.

  • Poster presentation from 12:30-14:30 CEST (06:30-08:30 EDT) on Thursday 26 July (Abstract #5718); Poster Exhibition area, Hall 1, next to the Global Village (ground floor, by the Main Entrance)

DIAMOND: Interim findings from the Phase 3 DIAMOND trial will provide evidence on the use of SYMTUZATM for the treatment of HIV-1 within community programs that use a Test-to-Treat model.

  • Poster presentation from 12:30-14:30 CEST (06:30-08:30 EDT) on Wednesday 25 July (Abstract #5095); Poster Exhibition area, Hall 1, next to the Global Village (ground floor, by the Main Entrance)

Final results of pilot study with darunavir/cobicistat/rilpivirine
PREZENT: Data will provide a first look at the final 96-week results of a pilot study into darunavir with cobicistat and ripilvirine in HIV-positive treatment-nave participants.

  • Poster presentation in partnership with IIS from 12:30-14:30 CEST (06:30-08:30 EDT) on Thursday 26 July (Abstract #4347); Poster Exhibition area, Hall 1, next to the Global Village (ground floor, by the Main Entrance)

Longer-term data for JULUCA, the first licensed two-drug maintenance treatment for HIV
SWORD 1 and 2: Data presented will show the evidence for durable maintenance of HIV-1 suppression to 100 weeks with a two-drug, single-tablet regimen combining ViiV Healthcare’s dolutegravir and Janssen’s rilpivirine, highlighting how it is possible to reduce cumulative ARV exposure while maintaining virological suppression.

  • Poster presentation by ViiV Healthcare from 12:30-14:30 CEST (06:30-08:30 EDT) on Thursday 26 July (Abstract #11730); Poster Exhibition area, Hall 1, next to the Global Village (ground floor, by the Main Entrance)

Results from Phase 2b study of an investigational two-drug long-acting injectable regimen comprising of ViiV’s cabotegravir and Janssen’s rilpivirine
LATTE-2: Data will explore patient satisfaction with the long-acting injectable regimen.

  • Poster presentation by ViiV Healthcare from 12:30-14:30 CEST (06:30-08:30 EDT) on Thursday 26 July (Abstract #6001); Poster Exhibition area, Hall 1, next to the Global Village (ground floor, by the Main Entrance)

LATTE-2: Data will explore patient adherence to long-acting cabotegravir and rilpivirine injections through 96-weeks of maintenance therapy

  • Poster presentation by ViiV Healthcare from 12:30-14:30 CEST (06:30-08:30 EDT) on Thursday 26 July (Abstract #10659); Poster Exhibition area, Hall 1, next to the Global Village (ground floor, by the Main Entrance)

Cellphone intervention to promote adherence to antiretroviral therapy and improve standard of care

Multi-Octave: Data presented will show the effectiveness of using 2-way cellphone intervention (CPI) to boost 3rd line adherence in ART-experienced individuals.

  • Poster presentation by AIDS Clinical Trials Group from 12:30-14:30 CEST (06:30-08:30 EDT) on Thursday 26 July (Abstract #5097); Poster Exhibition area, Hall 1, next to the Global Village (ground floor, by the Main Entrance)

New data on dapivirine vaginal ring, including variation on packaging and branding to improve product appeal to women, and social and behavioral data around male experiences of ring

Testing potential names and branding of packaging to ensure product is culturally appropriate, acceptable and appealing to women at risk of HIV in high HIV burden countries.

  • Poster presentation by International Partnership for Microbicides from 12:30-14:30 CEST (06:30-08:30 EDT) on Wednesday 25 July (Abstract #8590); Poster Exhibition area, Hall 1, next to the Global Village (ground floor, by the Main Entrance)

An exploration of the perceptions and experiences of male sex partners of women participating in the 104-week Phase 3 study using the dapivirine ring, and how these could affect ring use.

  • Poster presentation by International Partnership for Microbicides from 12:30-14:30 CEST (06:30-08:30 EDT) on Thursday 26 July (Abstract #10591); Poster Exhibition area, Hall 1, next to the Global Village (ground floor, by the Main Entrance)

Further details on our work in HIV and the breadth of science being driven by Johnson & Johnson companies and their partners is available at jnj.com/HIV.

Latest News

President Joe Biden signs his first executive orders in the Oval Office

Biden Administration Already Hard at Work Enacting Numerous Beneficial Policies; Amanda Gorman is America’s New Superstar Poet; and More

President Joe Biden sworn in and new administration already hard at work. Just hours after his emotional, star-studded and highly protected inauguration took place on Jan. 20, President Joe Biden is already working on fulfilling campaign promises and undoing some of the most egregious acts carried out by his predecessor….

Trump commission attempts racist whitewashing of history

Trump Commission Attempts Racist Whitewashing of History; Colorado Rep. Lauren Boebert Probed for Potential Role in Capitol Insurrection; and More

Trump commission’s “1776 Report” attempts racist whitewashing of history In the highly controversial “1776 Report” released by the Trump administration yesterday, the outgoing GOP party doesn’t just try to present a nonpartisan, “patriotic” look at the nation’s history (as the President had promised the report would do) it fully rewrites…

Flint, Michigan water plant

Ex-Michigan Governor Charged for Racist Lead Poisoning of Flint Water Supply; COVID-19 Vaccines Not Increasing in Availability; Democrats Plan to Repeal Trump Rules; and More

Former Michigan Governor formally charged for poisoning thousands of predominantly Black Flint citizens with water containing lead. In 2014, when the city of Flint was forced by the state to begin taking its water supply from the Flint river rather than using water from nearby Detroit as it had for…

NYPD under suit

NYPD Sued for Years of Racial Abuse and Use of Excessive Force; Trump Administration Approves Discrimination Against LGBTQ individuals; and More

NYPD sued by Attorney General for years of racial abuse and use of excessive force. In what’s been called a “landmark lawsuit,” The New York Times has reported that New York state Attorney General Letitia James is suing the city of New York, the mayor and the NYPD’s leaders, alleging…

NBCUniversal News Group Launches NBCU Academy, Offering Training to Universities and Community Colleges

NBCUniversal News Group launched NBCU Academy, a new, innovative, multiplatform journalism training and development program for four-year university and community college students through education, on-campus training and online programming. Originally published on corporate.comcast.com. The initiative includes a curated onsite curriculum for hands-on learning experience with world-class NBCU News Group journalists,…

Kaiser

Kaiser Permanente: Committing $8.15M for Racial Equity

Originally published on about.kaiserpermanente.org. Grants to grassroots and nonprofit organizations will help address structural racism and practices that prevent communities of color from achieving good health and well-being. Kaiser Permanente (DiversityInc Hall of Fame), the nation’s largest integrated, nonprofit health system, has awarded $8.15 million to support dozens of nonprofit…